Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis

Company Overview - Organovo Holdings, Inc. is a clinical stage biotechnology company focused on developing novel treatment approaches for inflammatory bowel disease (IBD), including ulcerative colitis [1][3] - The company utilizes proprietary technology to create three-dimensional (3D) human tissues that replicate key aspects of native human tissue [3] Product Development - The lead molecule, FXR314, is currently advancing towards Phase 2 investigation for IBD and has potential applications in metabolic liver disease and oncology [3] - The company aims to demonstrate the efficacy of FXR314 in its Phase 2a trial, building on strong preclinical results and promising data from 3D human models of ulcerative colitis and Crohn's disease [2] Market Context - The market for IBD treatments is active, with significant mergers and acquisitions, exemplified by Lilly's acquisition of Morphic for $3.2 billion following strong Phase 2a results [2] - The company is optimistic about its near-term opportunities to showcase the value of FXR314 in the competitive landscape of IBD treatments [2]